Plans to launch the first biosimilar of Enbrel (etanercept, Amgen Inc.) in Europe are taking a big step forward with receipt by Samsung Bioepis Co. Ltd. of a positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP). If approved by the European Commission (EC) as expected, it would become the first subcutaneous anti-TNF biosimilar there. It is one of three Bioepis biosimilars that Biogen Inc. has rights to commercialize in the EU and other countries.